[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinson-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinson-disease":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,469,0,25,[9,42,72,93,115,141,169,191,223,249,271,298,321,341,358,381,411,439,463,483,503,525,550,567,597],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100551933","phase-1-a-two-part-single-and-multiple-ascending-dose-trial-of-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-lbt-3627-in-healthy-participants-and-in-participants-with-parkinsons-disease-100551933",false,"NCT06466525","A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.","Both cohorts (Healthy Volunteers and Parkinson's Disease)\n\nKey inclusion criteria\n\n* Male or female, 30-89 years inclusive at screening\n* BMI 18-32 kg\u002Fm²\n* Vital signs, ECG (QTcF \\\u003C450 ms male \u002F \\\u003C470 ms female), and safety labs without clinically significant abnormality; no orthostatic hypotension\n* Women of non-childbearing potential, or using highly effective contraception per protocol\n\nKey exclusion criteria\n\n* Immunomodulators \u002F steroids - HV: any (incl. OTC) within 90 days; PD: systemic within 60 days and topical\u002Fnasal-inhaled OTC within 7 days (both waivable only with Sponsor approval)\n* Vaccine within 60 days (HV) \u002F 45 days (PD) of first dose\n* CoQ10 within 5 days\n* Inadequate renal function (CrCl ≤ 60 mL\u002Fmin; ≤ 79 if HV under 40), or LFTs \u002F bilirubin \\> 1.5× ULN\n* Clinically significant cardiovascular, hepatic, renal, neurological, or psychiatric disease\n* Active infection requiring systemic anti-infectives within 14 days; positive HBV\u002FHCV\u002FHIV serology\n\nParkinson's Disease participants - additional key inclusion criteria\n\n* PD diagnosis by a neurologist\u002Fgeriatrician, 6 months to \\\u003C 11 years before first dose, per MDS clinical diagnostic criteria\n* Hoehn \\& Yahr stage 1-3\n* If on levodopa: stable ≥ 2 months and able to withhold ≥ 12 hours (overnight) around dosing\u002Fassessments; if not, remain treatment-naïve through end of study\n\nParkinson's Disease participants - additional key exclusion criteria\n\n* Prior PD brain surgery, focused ultrasound, or neuromodulation; no anti-amyloid\u002Fanti-tau biologics\n* Antibiotics within 30 days; OTC pre\u002Fprobiotics; ≥ 3 unexplained falls in 12 months\n\nNote: Additional protocol-defined criteria apply.",true,"ALL","30 Years","89 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Phase I a\u002Fb SAD\u002FMAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.",[28],"Parkinson Disease","RECRUITING","2026-08-20",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":33},"2024-07-16",{"date":37,"type":22},"2027-02",{"name":39,"class":40},"Longevity Biotech Australia Pty Ltd (subsidiary)","INDUSTRY",2,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100644726","cross-system-effects-of-acute-intermittent-hypercapnia-based-interventions-in-pd-100644726","NCT07674264","Cross-System Effects of Acute Intermittent Hypercapnia-Based Interventions in PD","A Pilot Study of Acute Intermittent Hypercapnia-Based Interventions on Upper Airway and Axial Motor Function in Parkinson's Disease","Inclusion Criteria:\n\n1. adults 40 to 75 years of age (the latter to reduce the likelihood of cardiovascular disease)\n2. diagnosis of idiopathic Parkinsonism with Hoehn and Yahr stages 2-4\n3. medically stable with physician clearance\n4. ability to ambulate at least 10 feet with\u002Fwithout assistance\n5. ability to follow directions\n6. willing to abstain from blood donation for the duration of the study\n\nExclusion Criteria:\n\n1. additional neurologic conditions\n2. severe illness or infection, including respiratory\u002Fcardiovascular\u002Flung disease, or uncontrolled hypertension\n3. inspiratory stridor\n4. pregnancy due to unknown tAIH effects on a fetus, although females of childbearing age will not be excluded\\*\n5. cigarette smoking or vaping within 5 years\n6. history of head\u002Fneck\u002Flung cancer with the exception of basal cell carcinoma\n7. is currently participating in another research study that could influence the results from this study\n8. has deep brain stimulation electrodes implanted or has a history of deep brain stimulation\n9. faints or becomes lightheaded at the sight of blood\n\n   * If a female of childbearing potential indicates there is a chance she could be pregnant, she will be provided a pregnancy test and allowed to continue in the study if negative. This is because the fetal risks associated with intermittent hypoxia are unknown.","40 Years","75 Years",{"count":52,"type":22},32,[54],"NA","Parkinsonism impairs upper airway and axial motor control, leading to disordered breathing, reduced speech volume, and ineffective cough. Symptoms are poorly addressed by current therapies. This randomized pilot trial tests whether a single session of acute intermittent hypercapnic hypoxia (AIHH) or hypercapnic normoxia (AIHN) improves upper airway and axial motor function in Parkinsonism, and explores biomarker correlates of intervention responsiveness.",[28,57],"Parkinsonism",[59,60,61,62],"Axial function","Upper airway","Breathing","Acute Intermittent Hypercapnic Hypoxia","2026-08-19",{"date":32,"type":33},{"date":66,"type":33},"2026-08-12",{"date":68,"type":22},"2028-12-31",{"name":70,"class":71},"University of Florida","OTHER",{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":90,"locationsCount":92},"100550051","genetics-and-aerobic-exercise-to-slow-parkinsons-disease-trial-100550051","NCT06442033","Genetics and Aerobic Exercise to Slow Parkinson's Disease Trial","Genetics and Aerobic Exercise to Slow Parkinson's Disease (GEARS) Trial","GEARS","Inclusion Criteria:\n\n1. Adult with a diagnosis of PD by a physician or physician extender\n2. Hoehn and Yahr stage I-III\n3. Demonstrate the ability to safely mount and dismount a stationary cycle\n4. Reliable transportation to the community exercise facility\n5. Smartphone device for activity data monitoring\n6. On a stable dose of anti-parkinsonian medication\n\nExclusion Criteria:\n\n1. Participation in disease modifying PD-related clinical trial or study\n2. Diagnosis of dementia or any neurocognitive impairment that compromises one's ability to provide informed consent.\n3. Implanted deep brain stimulation electrodes or focused ultrasound for PD management\n4. Recommendation for medical clearance using the American College of Sports Medicine (ACSM) Preparticipation Health Screen a. If the ACSM screen recommends medical clearance, the participant must obtain medical clearance by their health care provider prior to participation.\n\nb. Those who choose not to obtain physician clearance will not be eligible for participation.\n\ne) A musculoskeletal issue (arthritis, osteoporosis, back problem) that would limit one's ability to engage in a cycling intervention f) Neurological disease other than Parkinson's disease (i.e. multiple sclerosis, stroke) g) Current cardiac arrhythmia","18 Years",{"count":82,"type":22},200,[54],"The proposed multi-site, Genetics and Aerobic Exercise to Slow PD (GEARS) Trial will, for the first time, determine the interplay between genetics and exercise in altering PD progression. In sum, 200 PD patients will be recruited from the Cleveland and Salt Lake City metro areas to participate in the Pedaling for Parkinson's (PFP) community-based exercise program. Participants will exercise at community-based sites 3x\u002Fweek for 12 months. All participants will undergo genotyping using an array that includes the genome backbone and common risk variants associated to increase risk for multiple neurological disorders including PD.",[28],{"date":32,"type":33},{"date":88,"type":33},"2024-08-23",{"date":68,"type":22},{"name":91,"class":71},"Jay Alberts",1,{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":102,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":92},"100517162","phase-4-personalized-real-time-dbs-and-pd-mechanisms-100517162","NCT06013956","Personalized Real-Time DBS and PD Mechanisms","Identifying Circuit Dynamics Underlying Motor Dysfunction in Parkinson's Disease Using Real-Time Neural Control","Key Inclusion Criteria:\n\n* Ability to provide informed consent.\n* Clinical diagnosis of idiopathic Parkinson's disease.\n* Determined, as per standard of care, to be a candidate for deep brain stimulation (DBS) surgery targeting the subthalamic nucleus.\n* Ability to tolerate delays in taking daily standard Parkinson's disease medications.\n\nKey Exclusion Criteria:\n\n* Secondary Parkinsonism, stroke, or progressive central nervous system disease other than Parkinson's disease.\n* Patient has a condition that, in the opinion of the investigators, would significantly increase the risk of interfering with study compliance, safety, or outcome.","80 Years",{"count":7,"type":22},[103],"PHASE4","A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia beta band (11-35 Hz) oscillations and resonance in the manifestation of Parkinson's disease (PD) motor signs using closed-loop electrical neurostimulation, levodopa medication, and computational modeling. The ultimate goal of this study is to inform the development of closed-loop neuromodulation technology that can be programmed and adjusted in real time based on patient-specific neural activity.",[28],[107],"Deep Brain Stimulation",{"date":30,"type":33},{"date":110,"type":33},"2023-08-29",{"date":112,"type":22},"2028-06-30",{"name":114,"class":71},"David Escobar",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":16,"sex":17,"minAge":123,"maxAge":4,"enrollmentInfo":124,"targetDuration":126,"studyType":127,"phases":4,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":92},"100430690","french-parkinsons-disease-cohort---ns-park-100430690","NCT04888364","French Parkinson's Disease Cohort - NS-PARK","Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)","NS-PARK","Inclusion Criteria:\n\n* Diagnosis of Parkinson's disease according to UK PD brain bak criteria\n* OR diagnosis of parkinsonian syndrome: multiple system atrophy, progressive supranuclear palsy, dementia with Lewy body, or corticobasal syndrom\n* OR Subjects at risk of PD defined as :\n\nNo symptom or diagnosis of Parkinson's disease nor parkinsonian syndrome, and relative to a patient with a diagosis of PD or parkinsonian syndrome, or carrier of a known mutation responsible for a genetic form of PD or patient with a diagnosis of idiopathic REEM sleep disorder or prodromal form of PD as defined by MDS criteria (Berg et al., 2015)\n\nAND for all participants\n\n* Affiliated to social security\n* Age \\> 10 years\n\nExclusion Criteria:\n\n* Subject under legal protection\n* Subject who do not consent to the research\n* for the optional skin biopsy only: clinically significant coagulation abnormalities or anticoagulant treatment","10 Years",{"count":125,"type":22},30000,"15 Years","OBSERVATIONAL","The aim of NS-PARK cohort are to describe the natural history of Parkinson's disease (PD), and to propose patients stratification models based on PD pathophysiological mechanisms. Patients are included at all PD expert centers in France. Standardized demographic, diagnosis, motor and non-motor symptoms evaluation, and treatment information are collected, and clinical data are updated at each visit of the patient at the center. A blood sampling is perform at baseline for genetic testing and implement an associated biocollection.",[28],[131,132],"Parkinson's disease","Genetics",{"date":30,"type":33},{"date":135,"type":33},"2021-06-16",{"date":137,"type":22},"2034-12-31",{"name":139,"class":140},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":100,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100591118","phase-2-a-study-to-determine-if-bhv-8000-is-effective-safe-and-tolerable-as-a-treatment-for-adults-living-with-early-parkinsons-disease-100591118","NCT06976268","A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease","A Phase 2\u002F3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease","Key Inclusion Criteria:\n\n* Male or female participants 40 to 80 years of age, inclusive, at the time of informed consent.\n* Meet the diagnostic criteria for \"Probable PD\" as assessed on the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD as assessed by the Investigator.\n* Have a clinician-documented diagnosis of idiopathic PD with an onset within 2 years of the Screening Visit\n\nKey Exclusion Criteria:\n\n* Medical history indicating a Parkinsonian syndrome other than idiopathic PD, including, but not limited to, progressive supranuclear gaze palsy, multiple system atrophy, drug-induced Parkinsonism, essential tremor, or primary dystonia.\n* Diagnosis of clinically significant central nervous system (CNS) disease other than PD.\n* Participants who are current smokers (defined as smoking \\[in any form, e.g., tobacco smoke, electronic cigarettes, etc.\\] )\n* Treatment with PD medication(s)\n* Any other condition(s) that may compromise participant safety, interfere with study conduct, or jeopardize the potential proper interpretation of study results, in the opinion of the investigator.",{"count":149,"type":22},550,[151,152],"PHASE2","PHASE3","A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.",[28],[156,157,158,159],"Early Parkinson's Disease","Parkinson's Disease","Early stage Parkinson's Disease","treatment naiive early Parkinson's Disease","2026-08-17",{"date":63,"type":33},{"date":163,"type":33},"2025-05-28",{"date":165,"type":22},"2028-09",{"name":167,"class":40},"Biohaven Therapeutics Ltd.",17,{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":17,"minAge":176,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":92},"100634759","phase-1-a-pilot-study-of-in-lab-dynamic-standing-in-parkinsons-disease-100634759","NCT07543861","A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease","FOGSTAND","Inclusion Criteria:\n\n* Diagnosis of Parkinson's Disease\n\nExclusion Criteria:\n\n* Inability to stand or walk without an assistive device\n* History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, or medication side effects\n* Any other history of medical or psychiatric comorbidity, precluding safe participation in the project.\n* History of symptomatic cardiovascular or pulmonary disease\n* History of active rheumatic arthritis\n* History of stroke or other neurologic conditions with significant residual sensorimotor deficits\n* History of disabling chronic pain syndrome requiring narcotic analgesics\n* Evidence of dementia (Mini Mental State Exam (or Montreal Cognitive Assessment test) \\\u003C24 and significant impairment in activities of daily living)\n* Venous ulcerative stasis or severe varicosities.\n* Pregnancy as determined by urine pregnancy test prior to DXA procedure in women of childbearing potential.","50 Years",{"count":178,"type":22},5,[25],"This research is studying the use of a new type of standing desk in a small number of people to learn about the user experience for people with Parkinson's disease. 12 4-hour sessions will be performed to test the primary hypothesis that dynamic standing improves gait function compared to static standing and control sitting. This study has 2 phases. Phase 1 will be an open-label study and Phase 2 will be an in-lab randomized controlled trial pilot study. This is phase 1 of the study.",[28],"2026-08-11",{"date":184,"type":33},"2026-08-14",{"date":186,"type":33},"2026-05-15",{"date":188,"type":22},"2027-03",{"name":190,"class":71},"University of Michigan",{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":212,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":92},"100545064","using-the-ehr-to-advance-genomic-medicine-across-a-diverse-health-system-100545064","NCT06377033","Using the EHR to Advance Genomic Medicine Across a Diverse Health System","Using Behavioral Economics and Implementation Science to Advance the Use of Genomic Medicine Utilizing an EHR Infrastructure Across a Diverse Health System","Inclusion Criteria:\n\n* 18 years of age or older\n* diagnosed with one of the study conditions\n\nExclusion Criteria:\n\n* Under 18 years of age\n* not diagnosed with one of the study conditions",{"count":199,"type":22},1000,[54],"Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place.\n\nInnovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and\u002For patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI's Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management.",[203,204,205,206,28,207,208,209,210,211],"Genetic Predisposition","Paraganglioma","Pheochromocytoma","ALS","Polyneuropathies","Frontotemporal Dementia","Alzheimer Disease","Cardiomyopathy Non-ischemic","Thoracic Aortic Aneurysm",[213,214,215],"Genetic testing","Genomic medicine","Electronic health record",{"date":184,"type":33},{"date":218,"type":33},"2024-06-10",{"date":220,"type":22},"2027-06-30",{"name":222,"class":71},"University of Pennsylvania",{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":240,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":4},"100651793","unilateral-and-staged-bilateral-pallidothalamic-tractotomy-using-exablate-mrgfus-in-advanced-parkinsons-disease-100651793","NCT07764874","Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.","An MR Guided Focused Ultrasound (MRgFUS) Randomized Trial Using the Exablate Neuro System to Assess the Effectiveness and Safety Outcomes of Unilateral and Staged Bilateral Ablation in the Subthalamic Region Involving the Pallidothalamic Tract (PTT) in Advanced Parkinson's Disease (PD) With Motor Complications.","FREEDOM","Inclusion Criteria:\n\n1. Men or women, age 30 years and older\n2. Subject is able and willing to give informed consent and able to attend all study visits\n3. Subject with a diagnosis of idiopathic PD by UK Brain Bank Criteria as confirmed by a movement disorder neurologist at the site.\n4. Subject is interested in receiving bilateral treatment if they qualify.\n5. Subject is Levodopa responsive as defined by at least a 30% reduction in MDS-UPDRS motor subscale in the ON vs OFF medication state.\n6. Subject has MDS-UPDRS Part III OFF ULE score of ≥ 15 on each side in the meds OFF condition.\n7. Subject experiencing motor complications of PD on optimum medical treatment characterized by dyskinesia (MDS-UPDRS item 4.2 score of ≥ 2) OR Motor fluctuations (MDS-UPDRS item 4.4 score of ≥ 2)\n8. Subject is on a stable dose of all PD medications for 30 days prior to screening visit PD assessments as determined by medical records\n9. Subject is able to communicate sensations during the Exablate procedure.\n10. Subject's pallidothalamic region can be targeted by the Exablate device.\n\nExclusion Criteria:\n\n1. Subject with severe premorbid risks as specified in the MDS-UPDRS Part II subsection motor aspects of experiences of daily living scores:\n\n   1. 3 or 4 on question 2.1 (speech) OR\n   2. 3 or 4 on question 2.3 (chewing and swallowing) OR\n   3. 4 on question 2.2 (saliva and drooling).\n2. Subject where there is suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications.\n3. Subject has an MMSE score \\\u003C 24.\n4. Subject has other central neurodegenerative disease suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer's disease.\n5. Subject with unstable psychiatric disease, uncontrolled depressive symptoms, psychosis, delusions, hallucinations, or suicidal ideation.\n6. Female subject who is pregnant.\n7. Female subject of childbearing potential not willing to use contraceptives throughout the duration of the study (\\~ 24 months)\n8. Subject exhibiting any behavior(s) consistent with ethanol or substance abuse.\n9. Subject with unstable cardiac status or severe hypertension.\n10. Subject with history of abnormal bleeding, hemorrhage, or coagulopathy.\n11. Subject with cerebrovascular disease.\n12. Subject is receiving anticoagulant (e.g., warfarin) or antiplatelet (e.g., aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g., Avastin) within one month of focused ultrasound procedure.\n13. Subject with advanced kidney disease or on dialysis.\n14. Subject with a history of seizures within the past year.\n15. Subject with a brain tumor.\n16. Subject with life-threatening systemic disease (e.g. HIV, liver failure, blood dyscrasias, etc.).\n17. Subject with any illness that in the investigator's opinion precludes participation in this study.\n18. Subject with standard contraindications for MR imaging such as implanted metallic devices.\n19. Subject who had prior deep brain stimulation of the basal ganglia or thalamus.\n20. Subject who is unable to tolerate the required prolonged stationary supine position during treatment.\n21. Subject who has an Overall Skull Density Ratio of less than 0.40 as calculated from the screening CT (if this is the only exclusion, subject can participate in the study as part of the reference group).\n22. Subject who is participating in another clinical investigation with an active treatment arm\n23. Subject who is unable to communicate with the investigator and staff.\n24. Subject who is in a nursing home in the last 30 days.\n\n    Additional Exclusion Criteria for Staged Bilateral PTT procedure\n25. Clinically significant neurological event of dysphagia, abnormal speech function, or gait abnormalities that are moderate to severe following first procedure.",{"count":232,"type":22},120,[54],"This study is a randomized clinical trial evaluating a focused ultrasound treatment for people with advanced Parkinson's disease (PD) who have disabling motor complications and symptoms.\n\nThe study uses the Exablate Neuro System, which delivers MR-guided Focused Ultrasound (MRgFUS). This technology focuses ultrasound energy on a specific brain target and generates heat to create a small lesion (ablation) without making a surgical incision.\n\nThe target in this study is the Pallidothalamic Tract (PTT), a pathway involved in the abnormal brain circuits that contribute to Parkinson's symptoms and complications.\n\nThis study is evaluating whether treating one side of the brain or treating both sides (in separate procedures) provides better outcomes for people with advanced Parkinson's disease who have motor complications and symptoms.\n\nThe main outcome measure is the change in the MDS-UPDRS Part III Upper\u002FLower Extremity (ULE) score at 3 months after first and second side treatment, compared with the respective control groups.\n\nMDS-UPDRS Part III is a standard clinical scale used to assess Parkinson's motor symptoms. ULE score focuses on motor function in the arms and legs. Assessments are performed in the OFF-medication state, meaning Parkinson's medications are temporarily withheld so that the treatment effect can be measured more accurately.\n\nIn addition improvement in motor complications will be assessed with MDS-UPDRS Part IV and Patient diaries.",[28],[237,238,239],"Exablate","MRgFUS","Pallidothalamic Tract","NOT_YET_RECRUITING","2026-08-10",{"date":184,"type":33},{"date":244,"type":22},"2026-09",{"date":246,"type":22},"2031-06",{"name":248,"class":40},"InSightec",{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":16,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":92},"100650789","young-onset-parkinsons-disease-subtypes-and-pathogenic-mechanisms-100650789","NCT07752355","Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms","YOPD","Inclusion Criteria:\n\nYOPD cohort:\n\n1. Male or female 18 years or older (inclusive) of any race and ethnicity\n2. Diagnosis of Parkinson's disease (PD) confirmed by a movement disorder specialist and with an age of onset of less than or equal to the age of 50 years old\n3. Willingness to undergo a skin punch biopsy\n\nLOPD cohort:\n\n1. Male or female 18 years or older (inclusive) of any race and ethnicity\n2. Diagnosis of PD confirmed by a movement disorder specialist and with an age of onset after the age of 50 years\n\nHealthy Control cohort:\n\n1. Male or female 18 years or older (inclusive) of any race and ethnicity\n2. Never been diagnosed with PD as reported by medical history and as assessed by study PI\n\nExclusion Criteria:\n\n1. Diagnosis of atypical parkinsonism (i.e. progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy) or secondary parkinsonism (i.e. normal pressure hydrocephalus, drug-induced parkinsonism).\n2. Clinical history of autoimmune or chronic inflammatory disorder or exposure to chronic immunosuppressant or immunomodulatory medications.\n3. Pregnancy\n4. Dermatological conditions that would prevent performing skin punch biopsies",{"count":257,"type":22},250,"Young Onset Parkinson's disease (YOPD) refers to a group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient's life. Current knowledge regarding the mechanisms leading to development of Parkinson's disease in younger individuals is lacking, but their understanding is crucial for the successful design of therapeutic strategies and stratifying patients for clinical trials. With this research the investigators aim to clarify the contribution of relevant biological processes in patients with Young onset Parkinson's disease to help understanding disease mechanisms and biomarkers.",[260,28],"Young Onset Parkinson Disease",[260,28,262,263],"Early Onset Parkinson Disease","EOPD",{"date":66,"type":33},{"date":266,"type":33},"2024-02-28",{"date":268,"type":22},"2028-10-31",{"name":270,"class":71},"NYU Langone Health",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":16,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":240,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":4},"100650624","brain-dopamine-biomarker-100650624","NCT07748715","Brain Dopamine Biomarker","Blue Color Processing in the Eye as a Biomarker of Brain Dopamine","B3-4D","Inclusion Criteria:\n\n* Parkinson's subjects will have received physician verified diagnosis of the disease and be on a dopaminergic medication for at least 3 months\n\nExclusion Criteria:\n\n* Any movement, strength, or balance assessments that may pose a potential risk for injury\n* Individuals with a history of photosensitive epilepsy or seizure activity triggered by visual stimuli\n* Current use of antipsychotics, stimulants, or other medications known to affect central dopaminergic transmission\n* Pregnancy\n* Recent ocular surgery\n* Phenylketonuria\n* (PD participants) not cognitively intact and not able to consent for themselves\n* (non-PD subjects) a pre-screening survey will assess medication use and neurological history\n* Ophthalmologic or visual system conditions that may interfere with stimulus delivery or retinal function. These include significant cataract (defined as LOCS III ≥ NC2\u002FNO2 or any media opacity that precludes adequate delivery of visual stimuli to the retina), active retinal or macular pathology (including age-related macular degeneration with significant drusen or geographic atrophy, diabetic retinopathy, retinal vein occlusion, or epiretinal membrane with foveal involvement), glaucoma, or any optic neuropathy.\n* Individuals with congenital color vision deficiencies, particularly tritan-spectrum defects\n* Ocular surgery within the past three months\n* Use of medications known to affect retinal electrophysiology (e.g., chronic hydroxychloroquine, vigabatrin, deferoxamine, or isotretinoin)\n* History of photosensitive epilepsy or visually triggered seizures (especially relevant given the use of bright visual stimuli and potential flicker paradigms)",{"count":280,"type":22},50,"This study is being conducted at the Morsani College of Medicine to determine whether signals recorded from the eyes and brain can be used as a noninvasive way to monitor dopamine function. Approximately 50 adults (25 with Parkinson's disease and 25 without Parkinson's disease) will participate. Participants will undergo electroretinography (ERG) and electroencephalography (EEG), which are FDA-approved, noninvasive devices that measure electrical activity from the retina and brain using sensors placed on the skin around the eyes and scalp. Participants with Parkinson's disease will be tested before and after taking their prescribed Parkinson's medication (e.g., Sinemet® \\[carbidopa\u002Flevodopa\\]). Participants without Parkinson's disease will receive a single dose of compounded levodopa\u002Fcarbidopa eye drops (an FDA-approved drug used in an unapproved ophthalmic formulation) in one eye and a placebo eye drop in the other eye. The placebo consists of the same vehicle solution without levodopa\u002Fcarbidopa and contains 0.1% ascorbic acid, 0.001% benzalkonium chloride, and phosphate-buffered saline. Randomization will be used to determine which eye receives the levodopa\u002Fcarbidopa eye drop and which eye receives the placebo. Researchers will compare measurements obtained before and after treatment to evaluate whether blue-light visual responses are associated with dopamine activity.",[28,283],"Healthy Adult Participants",[285,286,287,288,289,290],"dopamine","retina","biomarker","brain","electroretinography","blue light",{"date":66,"type":33},{"date":293,"type":22},"2026-10-01",{"date":295,"type":22},"2027-09-30",{"name":297,"class":71},"University of South Florida",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":305,"targetDuration":307,"studyType":127,"phases":4,"briefSummary":308,"conditions":309,"keywords":310,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":320},"100604105","sl-start---sublingual-apomorphine-schemes-of-titration-in-real-world-treatment-100604105","NCT07145190","SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment","SL-APO in the Treatment of Patients With Parkinson's Disease: a Real-world Evidence Study to Identify Titration and Usage Schemes - SL-START","Inclusion Criteria:\n\n* The patient is ≥ 18 years of age.\n* The patient has a clinical diagnosis of idiopathic Parkinson's disease.\n* The patient will initiate SL-APO for the treatment of OFF episodes according to the SmPC.\n* The patient is not currently on titration or maintenance dose for SL-APO.\n* The patient has provided written informed consent to participate in this study.\n\nExclusion Criteria:\n\n* The patient is participating in a clinical trial with an investigational drug.\n* The patient has presented with dementia or evidence of cognitive decline as determined by the investigator.\n* The patient has a history of psychotic disorder.\n* The patient presents any other contraindication according to the SL-APO SmPC.",{"count":306,"type":22},90,"6 Months","The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.",[28],[311,312],"Kynmobi","SL-APO",{"date":182,"type":33},{"date":315,"type":33},"2025-08-27",{"date":317,"type":22},"2028-02",{"name":319,"class":40},"Bial - Portela C S.A.",12,{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":16,"sex":17,"minAge":80,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":23,"phases":330,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":92},"100538342","early-phase-1-longitudinal-tspo-pet-imaging-with-18fdpa-714-in-ppmi-ppmi-dpa-714-pet-imaging-100538342","NCT06289582","Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)","Inclusion Criteria:\n\n* A prodromal PD and Healthy participant enrolled in PPMI Clinical protocol\n* A PD participant enrolled in PPMI Clinical protocol who has not started symptomatic treatment at time of enrollment or in the first 2 years of participation.\n* Able to provide informed consent\n* Must have screening genetic testing documenting high binder at the at the known TSPO gene polymorphism (rs6971)\n* Male or Female (Females must meet additional criteria specified below, as applicable)\n\n  • Females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of \\[18F\\]DPA-714\n* Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).\n* Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.\n\n  * Females of childbearing potential must not be pregnant, breastfeeding or lactating.\n  * Includes a negative urine pregnancy test prior to injection of \\[18F\\]DPA-714 on day of PET scan.\n\nExclusion Criteria:\n\n* Exposure to a total effective dose equivalent of 50 millisievert (mSv) for the whole body, which is the annual limit established by the US Code of Federal Regulations , during the past year.\n* Any other medical or psychiatric condition or lab abnormality, which in the opinion of the Site Investigator might preclude participation.","99 Years",{"count":329,"type":22},60,[331],"EARLY_PHASE1","The overall goal of this protocol is to investigate \\[18F\\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \\[18F\\]DPA-714 binding in PD participants during a 24-month interval.\n\nPrimary Objectives\n\n* To compare \\[18F\\]DPA-714 binding in prodromal and manifest PD and healthy volunteers.\n* To determine the longitudinal change in \\[18F\\]DPA-714 during a 24-month interval for prodromal and early initially untreated PD participants.\n\nSecondary Objectives\n\n* To evaluate the correlation between baseline \\[18F\\]DPA-714 and PPMI clinical and biomarker outcomes.\n* To evaluate the correlation between the longitudinal change of \\[18F\\]DPA-714 and PPMI clinical and biomarker outcomes\n* To acquire safety data following injection of \\[18F\\]DPA-714",[28],{"date":66,"type":33},{"date":336,"type":33},"2024-08-14",{"date":338,"type":22},"2028-06",{"name":340,"class":71},"University of Alabama at Birmingham",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":350,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":357,"locationsCount":92},"100320873","phase-1-the-university-of-alabama-at-birmingham-uab-neuroinflammation-in-parkinsons-disease-tspo--positron-emission-tomography-pet-substudy-100320873","NCT03457493","The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy","UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy","Inclusion Criteria for all cohorts:\n\n1. Enrollment in either the UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) study or UAB Longitudinal \\[18F\\]DPA-714 Imaging in a Parkinson Disease Cohort study under the separate UAB-approved research protocols (IRB-300001745 and IRB-300011684 respectively, PI Yacoubian)\n2. Negative urine or serum Human chorionic gonadotropin (hCG) test within 2 days of \\[18F\\]DPA-714-PET administration in women of childbearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.\n3. High or mixed affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971.\n\nExclusion Criteria for all cohorts:\n\n1. Meets any exclusion criteria for the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) study or UAB Longitudinal \\[18F\\]DPA-714 Imaging in a Parkinson's Disease Cohort study.\n2. Contraindication to MRI and\u002For PET imaging\n3. Inability to participate in the imaging studies due to severity of PD or other medical comorbidities.\n4. Low-affinity binder for TSPO ligands based on genotyping for SNP rs6971.\n\nInclusion Criteria specific for UDALL 5-year Follow-up Cohort\n\n1\\. Parkinson's Disease participant enrolled in UDALL Baseline Cohort. Baseline imaging to be completed no more than 6 years prior.\n\nInclusion of Women and Minorities\n\nParticipants 30 years of age or older will be eligible for study participation. No other discriminatory factors, including age, sex, or ethnic background will be used to determine eligibility. Every effort will be made to ensure that minorities are recruited for study participation.",{"count":349,"type":22},205,[25,151],"The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia\u002Fmacrophages using the PET ligand \\[18F\\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \\[18F\\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \\[18F\\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia\u002Fmacrophages and provides a non-invasive measure of neuroinflammation. The amount and distribution of \\[18F\\]DPA-714 in the brain will be correlated to clinical data acquired through the separate ongoing UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) and Longitudinal \\[18F\\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The primary objective of this study is to determine if patients with PD have higher levels of neuroinflammation than healthy controls as measured with \\[18F\\]DPA-714-PET\u002FMRI.",[28],{"date":66,"type":33},{"date":355,"type":33},"2018-03-22",{"date":338,"type":22},{"name":340,"class":71},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":17,"minAge":365,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":380},"100632419","a-trial-of-lu-af28996-in-participants-with-parkinsons-disease-pd-100632419","NCT07513441","A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)","Interventional, Open-label, Trial Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF28996 in Chinese Men and Women With Parkinson's Disease","Key Inclusion Criteria:\n\n* The participant is Chinese, defined as having four Chinese grandparents being born in China.\n* The participant is diagnosed with idiopathic Parkinson's disease (consistent with the United Kingdom PD Society Brain Bank Criteria for the Diagnosis of PD).\n* The participant's Modified Hoehn and Yahr score is ≥2 and ≤4 (in OFF) and ≤3 in the ON state.\n* The participant experiences well recognizable and predictable motor fluctuations in the awake time including predictable morning OFF episodes causing clinically significant disability during the last 3 months prior to screening, as evaluated by the investigator.\n\nKey Exclusion Criteria:\n\n* The participant has received oral or transdermal dopamine agonist treatment ≤4 weeks prior to screening.\n* The participant has undergone a neurosurgical intervention for Parkinson's disease (such as pallidotomy, thalamotomy, foetal or stem cell transplantation or deep brain stimulation).\n* The participant has any other disorder for which the treatment takes priority over treatment of Parkinson's disease or is likely to interfere with trial treatment or impair treatment compliance.\n* The participant has received Traditional Chinese Medicine treatment ≤4 weeks prior to screening.\n\nNote: Other protocol-defined inclusion and exclusion criteria may apply.","35 Years","85 Years",{"count":368,"type":22},10,[25],"The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.",[28],"2026-08-07",{"date":241,"type":33},{"date":375,"type":33},"2026-05-26",{"date":377,"type":22},"2027-05-31",{"name":379,"class":40},"H. Lundbeck A\u002FS",4,{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":410},"100626232","phase-2-a-study-to-evaluate-the-effectiveness-of-two-doses-of-ap-472-as-adjunctive-therapy-to-levodopa-in-parkinsons-disease-pd-participants-with-motor-fluctuations-100626232","NCT07432958","A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations","Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations","Key Inclusion Criteria:\n\nParticipants must meet all of the following criteria to take part in the study:\n\n1. Be a man or woman between 30 and 80 years of age at the time of screening.\n2. Have a diagnosis of Parkinson's disease, confirmed using standard medical criteria, including slowness of movement and symptoms that affect one side of the body more than the other.\n3. Have mild to moderate Parkinson's disease, defined as stage 3 or lower on the Hoehn and Yahr scale when medications are working (\"ON\" state).\n4. Experience an average of at least 3 hours of OFF time per day, based on home symptom diaries, with at least 2.5 hours of OFF time each day during the baseline period.\n5. Have a Montreal Cognitive Assessment (MoCA) score of 24 or higher at screening.\n6. Be able to walk independently, with or without the use of a walking aid.\n7. Be able to swallow oral medication.\n8. Have been on a stable Parkinson's medication regimen for at least 4 weeks before screening. Medications known as MAO-B inhibitors must have been stable for at least 12 weeks.\n9. Be taking levodopa at least four times daily (immediate- or controlled-release formulations) or three times daily (extended-release formulations such as Rytary or Crexont).\n\nKey Exclusion Criteria:\n\nParticipants cannot take part in the study if any of the following apply:\n\n1. Have a form of parkinsonism that is not typical Parkinson's disease, such as secondary or atypical parkinsonism.\n2. Have previously received, or plan to receive during the study, advanced Parkinson's therapies such as continuous levodopa or dopamine delivery systems, or Parkinson's disease-related brain surgery.\n3. Have dyskinesias (involuntary movements) that are severe enough, in the study doctor's opinion, to interfere with participation.\n4. Have a history of only certain types of dyskinesias (such as OFF-state, diphasic, myoclonic, or dystonic dyskinesias) without typical peak-dose dyskinesias.\n5. Are currently taking medications that block dopamine, except for low-dose quetiapine (up to 50 mg per day) used for insomnia.\n6. Routinely use on-demand \"rescue\" Parkinson's medications more than three times per week.",{"count":389,"type":22},150,[151],"This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.\n\nThe study will last about 12 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given.\n\nThe study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and an 8-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.",[28],[157,28,394,395,396,397,398,399,400,401,402],"Motor Fluctuations","OFF Time","Wearing-Off","Dyskinesia","AP-472","Adjunctive Therapy","Levodopa Adjunct","Positive Allosteric Modulator","Metabotropic Glutamate Receptor 4",{"date":182,"type":33},{"date":405,"type":33},"2026-02-25",{"date":407,"type":22},"2028-01-03",{"name":409,"class":40},"Appello Pharmaceuticals, Inc.",30,{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":100,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":424,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":178},"100593341","low-dose-carbon-monoxide-hbi-002-trial-to-evaluate-safety-tolerability-pk-and-biomarkers-in-parkinsons-disease-100593341","NCT07005180","Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease","A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, of HBI-002, an Oral Low-dose Carbon Monoxide (CO) Liquid Drug Product, Administered Daily Over 14 Days in Subjects With Parkinson's Disease (PD)","LoCaMoTE-PD","Inclusion Criteria:\n\nSubjects must meet the following criteria before being enrolled into the study:\n\n1. Signed informed consent.\n2. Male or female 40-80 years of age\n3. Non-smoker for at least 5 years with smoking defined as the use of smoked products (e.g. tobacco, marijuana, vaping or other)\n4. No smoking in the home (i.e. not living with a smoker)\n5. Body weight between 60 kg and 110 kg (inclusive) and with BMI less than 30 kg\u002Fm2 at screening and baseline\n6. Diagnosis of PD according to the Movement Disorder Society within 60 months of screening\n7. Hoehn and Yahr stage ≤ 3\n8. PD therapy: use of ≥100 mg TID levodopa or equivalent dose with additional carbidopa\u002Flevodopa or other antiparkinsonian medication (e.g. dopamine agonists \\[e.g., pramipexole, ropinirole, rotigotine\\] and monoamine oxidase inhibitors \\[e.g., selegiline or rasagiline\\]) for ≥30 days of stable dosing\n9. Good clinical response to levodopa therapy in the Site Investigator's opinion\n10. Negative pregnancy test for females of childbearing potential\n11. Where appropriate, subjects must be willing to use a highly effective method of contraception for the duration of the study and for 45 days thereafter\n\n    1. Male subjects, without a vasectomy, whose partner is of childbearing potential, must use a condom and be instructed that their female partner should use another form of contraception such as an IUD, diaphragm with spermicide, oral contraceptive, injectable progesterone, subdermal implant or a tubal ligation. Male subjects are prohibited from donating sperm for the duration of the study and 60 days following the end of study visit.\n    2. Female subjects of childbearing potential (not surgically sterilized and less than one year post-menopausal) should use a medically accepted form of contraception such as an IUD, diaphragm with spermicide, oral contraceptive, injectable progesterone, subdermal implant or a tubal ligation, and be instructed that their male partners should use a condom, if not vasectomized.\n12. Subjects must be healthy as defined by the following.\n\n    1. liver function: alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2X ULN\n    2. total bilirubin ≤ 1.5X ULN\n    3. renal function: creatinine clearance within normal range as assessed by Cockcroft and Gault calculation\n    4. carboxyhemoglobin level by venous blood gas ≤ 3.5%\n    5. the absence of current clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure, pulse rate, and respiratory rate measurement, 12-lead ECG, and clinical laboratory tests (hematology and clinical chemistries), as determined by the Site Investigator.\n    6. HbA1c \\\u003C 6.5%\n13. Subjects must have a study partner who can observe the subject for at least 4 hours after dosing at home (non-clinic days) in order to monitor for indications of CO toxicity.\n14. Subjects should live within 100 miles driving distance (door to door) of the site\u002Fclinic due to the need to carry study drug and ship study drug between the site\u002Fclinic and subject's home. Exceptions to this may be considered with Sponsor approval if it can be assured that the subject can transport study drug from clinic to home within two hours.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be ineligible for participation in the study:\n\n1. Clinical signs indicating a parkinsonian syndrome other than idiopathic PD, specifically:\n\n   1. Atypical parkinsonism, including parkinsonism due to drugs, metabolic disorders, encephalitis, cerebrovascular disease, normal pressure hydrocephalus, or other neurodegenerative disease.\n   2. Supranuclear gaze palsy\n   3. Signs of dementia (MoCA \\\u003C 22)\n   4. History of repeated strokes with stepwise progression of parkinsonian features\n   5. History of repeated head injury\n   6. History of definite encephalitis\n   7. Cerebellar signs\n   8. Early severe autonomic involvement\n   9. Babinski sign present\n2. Dysphagia with liquids\n3. History of exposure to or current treatment with neuroleptic drugs.\n4. History of dementia\n5. Oxygen saturation by transcutaneous measurement ≤ 95% confirmed on repeat assessment (any time prior to the first dose)\n6. Clinically significant ECG abnormalities (prolonged QTc greater than normal range, arrhythmia detected, bradycardia \\\u003C45 bpm, tachycardia \\>120 bpm, AV block \\[second or greater degree\\], bundle branch block) or vital sign abnormalities (systolic blood pressure lower than 90 or above 140 mm Hg, diastolic blood pressure lower than 50 or above 90 mm Hg, or heart rate less than 45 or above 100 bpm or arrhythmia), as determined by the Site Investigator.\n7. Renal failure requiring renal replacement therapy\n8. History of:\n\n   1. Serious cardiovascular diseases\n\n      * History of angina pectoris\n      * History of myocardial infarction or cardiac failure (NYHA from II to IV), myocardial insufficiency, symptomatic congestive heart failure with a documented ejection fraction below 45%\n      * History of serious cardiac arrhythmia other than stable atrial fibrillation\n      * History of stroke or occlusive peripheral vascular disease, brain vasospasm\n   2. Structural brain disease or cerebrovascular disease with clinical significance, including intracranial space-occupying lesion\n   3. Severe uncontrolled arterial hypertension\n   4. Severe pulmonary disease (asthma, COPD, other)\n   5. Specific psychiatric disorders, including hallucinations, delusions, pathologic gambling, alcohol or substance abuse or dependence\n   6. Type 1 or type 2 diabetes mellitus, impaired glucose tolerance, metabolic syndrome, maturity onset diabetes of the young, and gestational diabetes.\n   7. Pulmonary infiltrate or pneumonia within 6 months before screening or acute infection within 14 days of screening\n   8. Seizures \u002F epilepsy\n   9. Autoimmune disease requiring prescribed immunomodulatory therapy\n9. Alcohol abuse or dependence within one year prior to screening or regular use of alcohol within six months prior to the screening visit (defined as more than 14 units of alcohol per week; 1 Unit = 150 mL wine, 360 mL beer or 45 mL of 40% alcohol)\n10. History of drug abuse or dependence\n11. Positive result on drug screen for THC, cocaine, opiates\u002Fopioids, and methamphetamine\n12. History of cancer, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin more than 3 months prior\n13. Subject on domiciliary oxygen\n14. Positive HBsAg, aHCV, or aHIV\n15. Positive SARS-CoV-2 test within 10 days prior to study drug treatment\n16. Weight loss or gain of more than 5 kg within 3 months of screening\n17. Febrile or infective illness within 10 days prior to study drug treatment\n18. Moderate or more severe depression (Geriatric Depression Scale (GDS) ≥9)\n19. Suicide attempt or suicidal ideation within five years (Columbia-Suicide Severity Rating Scale (C-SSRS) defined as answering yes to items 4 or 5 on the C-SSRS, or history of suicide attempt in previous 5 years, or, in the Investigator's opinion, at serious risk of suicide.\n20. Positive pregnancy test or breast feeding for females\n21. Treatment with an investigational drug or medical device within the longer of 60 days or ten half-lives of the investigational agent\n22. Simultaneous participation or previous participation within 60 days before screening in another clinical drug or medical device study\n23. Persisting anemia with hemoglobin \\\u003C9 g\u002FdL\n24. Blood transfusion within 42 days prior to the first administration of study drug\n25. Exposure to any live vaccine within 28 days prior to study drug administration\n26. Syncope or other cause of loss of consciousness within the last 2 years\n27. Unwilling or unable to respond to follow-up phone calls\n28. Unwilling or unable to communicate with study site staff by telephone\n29. Unwilling or unable to comply with the requirements of the protocol\n30. Any coincident disease or condition that in the opinion of the Site Investigator will confound the assessment of HBI-002 safety or efficacy\n31. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Site Investigator, would make the subject inappropriate for entry into the study\n32. History of allergic reactions to any of the drug product excipients\n33. Contraindications to a routine lumbar puncture\n\n    1. History of thrombocytopenia (platelet count \\\u003C100,000)\n    2. History of coagulopathy (INR \\>1.3, PTT \\>ULN)\n    3. Current use of warfarin or other anticoagulants, or clopidogrel (Plavix)\n    4. History of lumbar surgery or severe spinal arthritis\n    5. Infection at LP site (may be included once resolved)",{"count":420,"type":22},36,[151],"A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).",[28],[28,425,426,427,428,429,430],"HBI-002","low dose carbon monoxide","heme oxygenase","HO-1","Nrf2","HIF-1α","2026-08-05",{"date":241,"type":33},{"date":434,"type":33},"2026-06-30",{"date":436,"type":22},"2027-03-31",{"name":438,"class":40},"Hillhurst Biopharmaceuticals, Inc.",{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":100,"enrollmentInfo":447,"targetDuration":4,"studyType":23,"phases":448,"briefSummary":449,"conditions":450,"keywords":452,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":461,"locationsCount":92},"100551069","phase-2-psilocybin-therapy-for-depression-in-parkinsons-disease-100551069","NCT06455293","Psilocybin Therapy for Depression in Parkinson's Disease","The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","PDP2","Inclusion Criteria:\n\n* Age 40 to 80\n* Comfortable speaking and writing in English\n* Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an \"on\" phase (time when medication\u002FDBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)\n* Currently experiencing depressive symptoms\n* Able to attend all in-person visits at UCSF as well as virtual visits\n* Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating\n\nExclusion Criteria:\n\n* Psychotic symptoms involving loss of insight\n* Significant cognitive impairment\n* Regular use of medications that may have problematic interactions with psilocybin\n* A health condition that makes this study unsafe or unfeasible, determined by study physicians",{"count":329,"type":22},[151],"The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.",[28,451],"Depression",[28,451,453,454,455],"Psilocybin","Psilocybin therapy","Movement disorder","2026-08-04",{"date":372,"type":33},{"date":459,"type":33},"2024-08-19",{"date":338,"type":22},{"name":462,"class":71},"Joshua Woolley, MD, PhD",{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":17,"minAge":176,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":472,"conditions":473,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":92},"100470003","blood-pressure-effects-on-cognition-and-brain-blood-flow-in-pd-100470003","NCT05400174","Blood Pressure Effects on Cognition and Brain Blood Flow in PD","Effects of Blood Pressure on Cognition and Cerebral Blood Flow in Parkinson Disease","Inclusion Criteria:\n\n1. Diagnosis of idiopathic Parkinson Disease using the Movement Disorders Society (MDS) Clinical Diagnostic Criteria\n2. Age at least 50 years old\n3. Hoehn \\& Yahr (H\\&Y) stages I-III (early to moderate-stage PD; able to walk without assistance\n4. Proficiency in the English language (native English speaker level)\n\nExclusion Criteria:\n\n1. Any involuntary movements (i.e., tremor or dyskinesia) \\> 3 cm in amplitude (ok if movements are treated with medication), since the motion artifact could interfere with blood pressure monitor data collection\n2. Dementia (including PD dementia)\n3. History of deep brain stimulation (DBS) surgery\n4. Any current unstable, active medical problem, e.g. decompensated heart failure, liver failure, pneumonia, etc.\n5. Moderate or severe carotid artery stenosis (according to North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria\n6. History of cerebral infarction or hemorrhage\n7. Uncontrolled diabetes or any other systemic disease causing autonomic failure\n8. Syncope (fainting) within the past week\n9. Illiteracy (unable to read)\n10. Taking antihypertensive medications or alpha-adrenergic blocking medications, since these can cause hypotension (see \\* below)\n11. Impairment of hearing or vision that is not corrected by devices (e.g., hearing aids or glasses)\n12. Currently pregnant (will be confirmed by women of child-bearing potential with a urine pregnancy test)\n13. Any other condition, which, in the opinion of the investigator, could place the participant at increased risk.\n\n    * Please note that persons may not participate if they are taking any of the following:\n\n      * medications to treat high blood pressure (called \"antihypertensives\") such as clonidine (Catapres), hydralazine, verapamil, diltiazem (Cartia), or medications ending in \"-olol\", \"-artan\", or \"-pril\")\n      * diuretics (also called \"water pills\") such as furosemide (Lasix), bumetanide (Bumex), hydrochlorothiazide (HCTZ; Microzide), or spironolactone (Aldactone)\n      * medications for enlarged prostate such as prazosin (Minipress), terazosin, doxazosin (Cardura), alfuzosin (Uroxatral), or tamsulosin (Flomax)\n\nIf persons are taking these medications and would like to participate in the study, they will be advised to discuss whether they may discontinue these medications for 48 hours before the study visit with their prescribing doctor.",{"count":329,"type":22},[54],"Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Besides causing symptoms that impair movement, PD also causes non-motor symptoms, such as problems thinking and orthostatic hypotension (OH), i.e., low blood pressure (BP) when standing. About one-third of people with PD have OH, which can cause sudden, temporary symptoms while upright, including lightheadedness, dizziness, and fainting. People with PD and OH can also experience problems thinking that happen only while upright and not while sitting - this can occur without other symptoms, such as feeling dizzy or faint. However, the level of low BP that can affect thinking remains unknown, and no guidelines exist for treating OH when it happens without symptoms. This is significant because OH could be a treatable risk factor for thinking problems in PD, but OH is often not treated if people do not report obvious symptoms.\n\nThis project's goal is to determine how BP affects brain function in PD. The proposed experiments will measure BP and brain blood flow continuously in real-time using innovative wearable technology. Persons with PD with OH and without OH will undergo repeated cognitive tests while supine (lying down) and while upright. I will study the associations between BP, thinking abilities, and brain blood flow, and will compare groups with and without OH. These findings could be important because if a certain level of BP correlates with thinking abilities, then treating OH in PD may prevent thinking problems, which would improve health-related quality of life and reduce disability and healthcare costs.",[28,474,475],"Orthostatic Hypotension","Dysautonomia",{"date":372,"type":33},{"date":478,"type":33},"2021-12-14",{"date":480,"type":22},"2027-01-15",{"name":482,"class":71},"University of California, San Diego",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":16,"sex":17,"minAge":176,"maxAge":366,"enrollmentInfo":489,"targetDuration":4,"studyType":23,"phases":491,"briefSummary":492,"conditions":493,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":92},"100466736","phase-4-characterization-of-the-serotonin-2a-receptor-selective-pet-tracer-18fmhmz-in-patients-with-neurodegenerative-diseases-100466736","NCT05357612","Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases","Inclusion Criteria:\n\n* Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants\n* Healthy arm - age and gender matched to patient arm\n* Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.\n* Study partner available for study visits\n\nExclusion Criteria:\n\n* Prior stroke or other uncontrolled serious neurological or medical illness\n* Contra-indication or inability to tolerate MRI scan\n* Use of serotonergic medications in the last 6 weeks\n* Incapable of providing independent consent.\n* Pregnant or breastfeeding women\n* psychosis due to a metabolic, toxic, or primary psychiatric disease\n* Deemed unable to complete neurocognitive testing\n* For PD Participants: current or prior use of pimavanserin\n* Use of antipsychotics in the last 2 weeks",{"count":490,"type":22},75,[103],"It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age\u002Fsex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\\[18F\\]MH.MZ in both populations.",[494,28,495],"Neurodegenerative Diseases","Parkinson Disease Psychosis",{"date":372,"type":33},{"date":498,"type":33},"2023-01-23",{"date":500,"type":22},"2027-08",{"name":502,"class":71},"Vanderbilt University Medical Center",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":510,"targetDuration":511,"studyType":127,"phases":4,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":380},"100558630","radiofrequency-rf-ablation-prospective-outcomes-study-for-central-nervous-system---rapid-for-cns-100558630","NCT06553625","Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS","Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System","Inclusion Criteria:\n\n* Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU)\n* Signed a valid, IRB\u002FEC\u002FREB-approved informed consent form\n\nExclusion Criteria:\n\n* Meets any contraindications per locally applicable Directions for Use (DFU)\n* Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments",{"count":82,"type":22},"24 Months","The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.",[28,514,515,516],"Dystonia","Essential Tremor","Movement Disorders","2026-08-03",{"date":456,"type":33},{"date":520,"type":33},"2024-01-29",{"date":522,"type":22},"2035-12",{"name":524,"class":40},"Boston Scientific Corporation",{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":532,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":535,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":240,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":546,"leadSponsor":548,"locationsCount":4},"100538613","the-effects-of-ischemic-conditioning-in-individuals-with-parkinsons-disease-100538613","NCT06293118","The Effects of Ischemic Conditioning in Individuals With Parkinson's Disease","The Chronic Effect of Ischemic Conditioning on Motor Function, Cognitive Performance, and Immune System in Individuals With Parkinson's Disease","Inclusion Criteria:\n\n* PD patients aged 40 years or older;\n* Diagnosis of PD without cognitive complaints or with complaints, but without impact on daily activities;\n\nExclusion Criteria:\n\n* Patients with uncontrolled diabetes mellitus or peripheral neuropathy;\n* Uncontrolled arterial hypertension (BP\\>160\u002F100mmHg);\n* Uncontrolled diabetes (Fasting glucose \\> 250mg\u002Fdl, peripheral retinopathy or diabetic ketoacidosis);\n* Uncontrolled dyslipidemia (total chol \\> 220mg\u002FdL);\n* Pre-existing autoimmune diseases;\n* Infectious conditions for less than 1 month;\n* Neurological problems that prevent training from being carried out;\n* History of anemia, cerebral vascular disease, myocardial infarction in the last 6 months;\n* Previous deep vein thrombosis;\n* Smoking \\\u003C 6 months;\n* Symptomatic peripheral arterial obstructive disease;\n* Cognitive dysfunction: Moca \\\u003C 24.","90 Years",{"count":534,"type":22},34,[54],"Ischemic conditioning (IC) is a promising therapy that can mimic the physiological effects of physical exercise. IC consists of using a cuff to measure blood pressure and calibrate 200 mmHg on the upper or lower limb. Thus, at alternating intervals of 5 minutes, ischemia or reperfusion occurs, depending on whether the cuff is inflated or deflated. IC induces changes in spinal cord excitability for the last reflex reactions of recruited motoneurons with improved balance control in healthy young people and improved learning in the elderly. The objective of the present study is to evaluate the chronic effect of IC on the motor function and cognitive performance of patients with Parkinson's disease. Furthermore, the investigators will evaluate secondary outcomes such as mobility, quality of life, and immunological responses.",[28],[539,540,541,542,543],"ischemic conditioning","immune system","motor function","cognitive performance","Parkinson disease",{"date":431,"type":33},{"date":293,"type":22},{"date":547,"type":22},"2028-09-01",{"name":549,"class":71},"Hospital Israelita Albert Einstein",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":566},"100336760","deep-brain-stimulation-dbs-retrospective-outcomes-study-100336760","NCT03664609","Deep Brain Stimulation (DBS) Retrospective Outcomes Study","Inclusion Criteria:\n\n* Must be previously treated with or eligible for implantation with a deep brain stimulation system\n\nExclusion Criteria:\n\n* No Exclusion Criteria",{"count":557,"type":22},5000,"The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.",[28,515,514],{"date":456,"type":33},{"date":562,"type":33},"2019-03-12",{"date":564,"type":22},"2028-12",{"name":524,"class":40},19,{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":23,"phases":574,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":240,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":92},"100650541","decoding-the-neural-mechanisms-underlying-postural-instability-and-gait-dysfunction-in-parkinsons-disease-100650541","NCT07748962","Decoding the Neural Mechanisms Underlying Postural Instability and Gait Dysfunction in Parkinson's Disease","Inclusion Criteria:\n\n* You have been diagnosed with Parkinson's disease\n* You already have a deep brain stimulation (DBS) device implanted as part of your medical care - specifically, the Medtronic Percept DBS device\n* Your DBS settings have been stable for at least 3 months\n* You experience freezing of gait (sudden inability to move your feet when trying to walk)\n* You are able to walk on your own for at least 10 minutes without assistance\n* You are willing to temporarily stop your Parkinson's medications and have your DBS settings adjusted for study testing\n* You are able to understand the study and provide consent to participate\n\nExclusion Criteria:\n\n* You have a neurological condition other than Parkinson's disease (such as stroke or multiple sclerosis)\n* You have been diagnosed with dementia or have difficulty understanding the study or giving consent\n* You currently have alcohol or substance abuse problems\n* You have hearing or vision problems that would make it difficult to use a virtual reality headset\n* You have any medical or mental health condition that, in the opinion of the study doctor, would make it unsafe or difficult for you to participate",{"count":178,"type":22},[54],"The purpose of this study is to learn how brain signals are related to freezing of gait (FOG) and balance problems in Parkinson's disease (PD) and to study how different deep brain stimulation (DBS) settings may affect these symptoms.",[28,577],"Freezing of Gait",[579,580,581,582,583,584,585,586,131,587],"Deep brain stimulation","Balance","Postural instability","Gait dysfunction","Virtual reality","Mixed reality","Percept","Falls","DBS","2026-07-31",{"date":590,"type":33},"2026-08-06",{"date":592,"type":22},"2026-09-18",{"date":594,"type":22},"2027-04-18",{"name":596,"class":71},"The Cleveland Clinic",{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":16,"sex":17,"minAge":603,"maxAge":532,"enrollmentInfo":604,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":605,"conditions":606,"keywords":608,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":92},"100380860","autoimmune-features-of-neurodegenerative-disorders-100380860","NCT04239079","Autoimmune Features of Neurodegenerative Disorders","PD and age matched controls:\n\nFor PD participants (n=30):\n\nInclusion criteria:\n\n* Clinical diagnosed PD based on UK Brain Bank criteria for the clinical diagnosis of PD. And must demonstrate two of the following three, as modified from BioFIND criteria: rest tremor, rigidity, or bradykinesia, with dopaminergic medication benefit\n* Age at recruitment ≥ 55\n* Age at motor onset \\> 45\n* PD onset age between 50-75 years\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* Atypical features indicative of a Parkinson-Plus disorder (Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD)) including cerebellar signs, supranuclear gaze palsy, apraxia and other cortical signs, or prominent autonomic failure, neuroleptic treatment at time of onset of parkinsonism, active treatment with a neuroleptic at time of study entry, history of repeated strokes with stepwise progression of parkinsonism, history of repeated head injury, history of definite encephalitis, prominent gait imbalance early in the course (\\\u003C 5 years)\n* History of Dementia\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent.\n\nFor age-matched control participants (n=30):\n\nInclusion criteria:\n\n* Ages ≥55 years old\n* With lack of PD in first-degree blood relatives\n* Montreal Cognitive Assessment (MoCA): ≥26\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent\n\nAD\u002FaMCI and age matched controls:\n\nFor AD\u002FaMCI participants (n=30):\n\nInclusion criteria:\n\n* Clinically diagnosed mild AD\u002Famnestic MCI. The severity will be accessed through the Clinical Dementia Rating Scale (CDR). CDR equal to 0.5 or 1 will be necessary to meet criteria. Participants with advanced AD stage will not be capable to give their consent.\n* Age ≥55 years old\n* Mini-Mental State Exam (MMSE): 20-26\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* Other forms of dementia including frontotemporal dementia or other dementia associated with parkinsonism such as Dementia with Lewy bodies (DLB), or Parkinson's disease Dementia (PDD), Progressive Supranuclear Palsy or corticobasal degeneration.\n* History of Parkinson's disease (PD)\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent\n\nFor age-matched control participants (n=30):\n\nInclusion criteria:\n\n* Healthy volunteers ≥55 years old\n* CDR: 0\n* MoCA: ≥26\n* Willingness to have genotyping and genetic studies\n\nExclusion criteria:\n\n* History of Parkinson's disease (PD)\n* Recent history of cancer (past 3 years), except skin cancer\n* Autoimmune disease\n* Disease of the immune system (e.g. chronic leukemia, HIV)\n* On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)\n* Inability to provide informed consent","55 Years",{"count":232,"type":22},"This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD). The investigators plan to recruit 30 PD, 30 AD\u002FAmnestic Mild Cognitive Impairment (aMCI), and 60 age matched healthy controls in this study to study the role of immune response in PD and AD.\n\nThe study involves up to two study visits involving brief questionnaires and blood draw of up to 250cc (approximately 17 tablespoons) to be collected. More ways to participate, including 1) smaller amount blood donation (up to 100cc per visit for 1-2 visits); and 2) participation via tele-visit and mobile phlebotomy visits (blood donation up to 50cc, \\~5 tubes, by a certified mobile phlebotomist at home\u002Flocation of choice) now available.",[28,209,607],"Mild Cognitive Impairment",[609,131,610,607],"Autoimmune features","Alzheimer's disease",{"date":456,"type":33},{"date":613,"type":33},"2019-05-01",{"date":615,"type":22},"2028-07",{"name":617,"class":71},"Columbia University"]